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Abstract: PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGC-
CCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients
treated between 1975 and 1990. MATERIALS AND METHODS Data on 9,728 men with metastatic
nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy
between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North Amer-
ica, and Australia. Clinical trial and registry data were included. Primary end points were progression-free
survival (PFS) and overall survival (OS). The survival estimates were updated for the current era. Ad-
ditionally, a novel prognostic model for PFS was developed in 3,543 patients with complete information
on potentially relevant variables. The results were validated in an independent data set. RESULTS
Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good
prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92%
(90%-94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75%
(71%-79%) versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In
patients with poor prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to
56) and the OS from 48% (95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic
model was developed and independently validated. This model identified a new cutoff of lactate dehy-
drogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional
adverse prognostic factors. An online calculator is provided (https://www.eortc.org/IGCCCG-Update).
CONCLUSION The IGCCCG Update model improves individual prognostication in metastatic nonsemi-
nomatous germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG
classification as adverse prognostic factors.
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PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role
in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990.
MATERIALS AND METHODS Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with
cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 insti-
tutions or collaborative groups in Europe, North America, and Australia. Clinical trial and registry data were in-
cluded. Primary end points were progression-free survival (PFS) and overall survival (OS). The survival estimates
were updated for the current era. Additionally, a novel prognostic model for PFS was developed in 3,543 patients
with complete information on potentially relevant variables. The results were validated in an independent data set.
RESULTS Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good
prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92% (90%-
94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75% (71%-79%)
versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In patients with poor
prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to 56) and the OS from 48%
(95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic model was developed and in-
dependently validated. This model identified a new cutoff of lactate dehydrogenase at a 2.5 upper limit of normal
and increasing age and presence of lung metastases as additional adverse prognostic factors. An online
calculator is provided (https://www.eortc.org/IGCCCG-Update).
CONCLUSION The IGCCCG Update model improves individual prognostication in metastatic nonseminomatous
germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG classification as
adverse prognostic factors.
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INTRODUCTION
About half of the patients with nonseminomatous germ
cell tumors (GCT) (nonseminomatous germ cell tu-
mors [NSGCT]) present with metastatic disease. Their
cure rate is highly variable depending on histology,
primary tumor location, tumor marker levels, and
metastatic sites. In 1997, the International Germ Cell
Cancer Collaborative Group (IGCCCG) published a
classification, which became the accepted interna-
tional standard and replaced all previous ones.1
In recent years, improved survival rates in metastatic
NSGCT have been reported, possibly because of
improved diagnostic tools, improved supportive care,
introduction of the IGCCCG prognostic classification
and tailored treatment according to this classification,
better guideline adherence with standard use of cis-
platin- and etoposide-based first-line treatments, more
stringent use of postchemotherapy surgery, improved
salvage treatments, and centralized management at
dedicated expert centers or a combination of these
factors.2–7
According to the original IGCCCG classification, met-
astatic NSGCT are split into good, intermediate, and
poor prognostic categories based on levels of alpha-
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(hCG), and lactate dehydrogenase (LDH) as well as the
presence of nonpulmonary visceral metastases (NPVM). In
addition, all primary mediastinal NSGCT are classified as
poor, irrespective of other factors.1 However, patients in-
cluded in the original IGCCCG analysis were treated be-
tween 1975 and 1990, and not all had received cisplatin or
etoposide, which would be the treatment backbone for
metastatic NSGCT today.3,7
The IGCCCG Update Consortium collected data on meta-
static NSGCT with two major goals: first, to validate the
original IGCCCG criteria and update survival probabilities in
a modern cohort and second, to explore additional prog-
nostic factors that may add granularity to the original
IGCCCG prognostic groups and explain some of the het-
erogeneities found within the groups of the original IGCCCG
classification.8
MATERIALS AND METHODS
The IGCCCG Update Consortium
The IGCCCG Update Consortium consisted of 30 institu-
tions or collaborative groups in Europe, North America, and
Australia. Potential contributors were identified through
contact between peers, supplemented by a PUBMED
search. The principal investigators of individual trials were
invited to participate in the initiative based on a written data
sharing agreement.
In addition, the coordinators of national cooperative groups
in GCT or principal physicians at large cancer centers were
contacted with respect to the availability of national or local
cancer registries in electronic format. Investigators were
asked to contribute consecutive patients. The Protocol
(online only) and the list of collected data items are
available in the Data Supplement (online only).
Data Collection
The purpose of the collaboration was to establish a com-
mon electronic database with data of patients with meta-
static GCT treated between 1990 and 2013: the IGCCCG
Update Data Warehouse. To ensure appropriate repre-
sentation of patients and because trials often limit eligibility
to specific IGCCCG prognostic groups, structured data from
national registries, databases, or large cohorts of single
center data on consecutively treated patients who fulfilled
the Protocol data and eligibility requirements were collected
in addition to data from clinical trials.
After signing of the data sharing agreements, patient-level
data were aggregated, normalized, and harmonized. Data
were processed centrally and stored in a secure format at
the headquarters of the European Organisation of Research
and Treatment of Cancer in Brussels, Belgium.
Patients and Data
Thirty participating members of the IGCCCG consortium
provided anonymized data on consecutive adult male
patients with metastatic NSGCT or primary retroperitoneal
or mediastinal NSGCT also when not metastatic.
All patients had to receive cisplatin- and etoposide-based
conventional-dose first-line treatment or upfront high-dose
chemotherapy requiring stem-cell support for NSGCT.
Patients with prior chemotherapy for metastatic disease,
those included in the original IGCCCG analysis, and pa-
tients with primary GCT of the brain were ineligible. Patients
treated with conventional chemotherapy had to receive
minimum three cycles; patients with less than three cycles
were allowed, provided that there was enough evidence
that at least three cycles were intended. The treatment
intended to be given to the patients was recorded where
available, and treatments actually given otherwise.
Data items included the original IGCCCG group, age, date of
metastatic diagnosis, and primary site; levels of serum AFP,
hCG, and LDH at diagnosis and before chemotherapy, and
the presence and location of metastases. The type and
number of chemotherapy cycles were obtained, and pro-
gression status, vital status, cause of death, and disease
status at last follow-up were recorded.
Trials and Cohorts
We asked for electronic databases of studies and cohorts
comprising a minimum of 100 eligible patients for inclusion
in the warehouse. Only databases of first-line chemother-
apy as described in the patient eligibility criteria were in-
cluded. Retrospective data of first-line treatments of
patients who were primarily referred for relapse were not
included, because it would have artificially inflated the
progression probabilities in the data warehouse.
End Points
Primary end points were progression-free survival (PFS)
and overall survival (OS). OS was defined as the time from
start of chemotherapy to death of any cause. PFS was
defined from start of chemotherapy to progression, defined
by radiological progression, unequivocal tumor marker
increase, or death, whichever came first. PFS was used for
the prognostic model training.
Statistical Methods
All patients with available PFS and/or OS information were
used to update the survival probabilities. Kaplan-Meier
estimates were used to update survival estimates accord-
ing to the original IGCCCG. 95% CI are provided via log-log
transform.9,10
To build a new prognostic model allowing for individual
prediction, an analysis set consisting of eligible patients
with all considered explanatory variables was created.
These variables were the prechemotherapy AFP and hCG
as continuous variables and LDH levels times upper limit of
normal (ULN), site of primary tumor, age (in years) as a
continuous variable, presence of NPVM and presence of
lung metastases. Patients with unspecified other primary
tumor site were excluded. The increase in risk because of
2 © 2021 by American Society of Clinical Oncology
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AFP and hCG elevations was modeled only for unequivocal
marker elevation, defined as AFP . 30 ng/mL and hCG .
5U/L, respectively. Values below those thresholds were
considered equivocal and were grouped with values
, ULN. Studies forming the analysis set were split into six
major clusters based on geographical considerations to
account for some of the heterogeneities between patient
populations. Details on these clusters are given in the Data
Supplement (online only).
Two thirds of studies forming each cluster were included in
the training set, whereas the remaining studies formed the
independent validation set. Because of the lower number of
events for OS, the prognostic IGCCCG Update model was
developed for PFS, based on all patients in the training set
with complete PFS information. Both end points were
administratively censored at 3 years to harmonize duration
of follow-up across data sources since most events had
occurred by this time (Appendix, online only).
All candidate variables were used for model building.
Continuous variables were assessed for linearity based on
graphical checks and transformed or categorized if war-
ranted. The experts from the steering committee identified
a priori the most likely clinically relevant interactions to be
considered as the interactions between the presence of
NPVM and the level of the prechemotherapy markers (AFP,
hCG, and LDH). These interactions were globally tested at
the 5% significance level.
The final IGCCCG Update model is defined in two parts: (1)
The prognostic score, which models the prognostic impact
of each covariate on PFS. The prognostic score of the final
IGCCCG Update model was obtained by incorporating all
candidate variables in a Cox proportional hazards model,
stratified on the six clusters previously specified. (2) The
baseline hazard, which models the risk of progression as a
function of time for patients who had baseline levels of all
prognostic factors entered in the model. The baseline
hazard for the final IGCCCGUpdate model was taken as the
average of the six cluster-specific baseline hazard using a
Royston-Parmar parametric model, with the score previ-
ously obtained as sole covariate.11
The performance of the final IGCCCG Update model was
investigated in the training and validation set. Overall
performance over time was assessed using an integrated
Brier score (IBS), which integrates the apparent estimate of
the prediction error over 3 years.12 Prediction accuracy was
assessed via calibration plots, whereas the discriminative
ability of the prognostic score was evaluated using time-
dependent area under the curve (AUC).13
The final IGCCCG Update model was graphically repre-
sented via nomograms.
All analyses were performed using SAS version 9.4 (Cary,




In total, data on 13,684 patients with GCT were received, of
whom 12,179 (89%) were eligible. Of these patients, 9,728
had been diagnosed as NSGCT based on histology and/or
unequivocal AFP elevations. Reasons for ineligibility are
listed in the CONSORT diagram (Fig 1). The original
IGCCCG groups could be calculated in 9,576 of 9,728
(98%) patients, whose data were used to update OS
probabilities. Among them, 7,313 patients were initially
recorded in local or national cohorts, whereas 2,263 came
from clinical trial databases. Because of inconsistent or
missing data, 9,420 (99%) patients were used to update
PFS probabilities.
Disease progression occurred in 2,190 patients, and 1,352
patients died. The PFSmedian follow-up was 6.4 years (7.4
years for cohorts and 3.8 years for trials), and 81% had
been followed for at least 3 years from start of chemo-
therapy (87% for cohorts and 64% for trials).
The analysis set consisted of 4,955 patients with NSGCT, in
whom potentially relevant covariates were available. The
analysis set was split between a training set of 3,570 pa-
tients (72%, 3,543 with PFS information) and a validation
set of 1,385 patients (28%, 1,360 with PFS information).
Table 1 shows the baseline characteristics of the 4,955
patients in the analysis set, divided between training and
validation sets. Slightly more patients in the validation set
had NPVM (poor prognosis IGCCCG) compared with the
training set. Additionally, the patients in the validation set
were treated more recently compared with patients in the
training set (83.6% of patients in the validation set were
treated after 2,000 v 60.5% in the training set). Finally,
97.6% of all trial patients were allocated to the training set.
A comparison between patients included or not included in
the prognostic model analysis set showed that the most
common reason for exclusion was missing information
about LDH (75.8%) (Data Supplement) and that there were
no differences in PFS or OS between patients included in or
excluded from the analysis set (Data Supplement).
Updated Outcomes by Original IGCCCG
Table 2 shows the updated 5-year OS and PFS probabilities
in the present series as compared with those in the original
IGCCCG publication.1 Corresponding Kaplan-Meier curves
of OS and PFS are presented in Figures 2A and 2B.
The 5-year OS significantly improved for all IGCCCG groups,
as shown by the nonoverlapping confidence intervals. In
contrast, 5-year PFS significantly improved only for poor
IGCCCG patients.
New Prognostic IGCCCG Update Model for Individual
Prediction of PFS
The training set for the prognostic model included 3,543
patients with complete information on potentially important
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IGCCCG prognostic groups available
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Analysis set for OS
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FIG 1. CONSORT diagram. IGCCCG, International Germ Cell Cancer Collaborative Group; OS, overall survival; PFS,
progression-free survival.
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TABLE 1. Baseline Characteristics for Patients in the Analysis Set
Baseline Characteristics
Analysis Set
Total (N 5 4,955)Training (n 5 3,570) Validation (n 5 1,385)
n (%) n (%) n (%)
Age at diagnosis of metastatic disease (years)
Median 28 30 29
Range 15-70 15-70 15-70
Q1-Q3 23-35 24-36 24-35
Original IGCCCG prognostic groups
Good 1,711 (47.9) 554 (40.0) 2,265 (45.7)
Intermediate 1,047 (29.3) 445 (32.1) 1,492 (30.1)
Poor 812 (22.7) 386 (27.9) 1,198 (24.2)
Progression-free survival status
No progression 2,762 (77.4) 1,038 (74.9) 3,800 (76.7)
Progression in the first 3 years 668 (18.7) 279 (20.1) 947 (19.1)
Progression after 3 years 113 (3.2) 43 (3.1) 156 (3.1)
Missing 27 (0.8) 25 (1.8) 52 (1.0)
Overall survival status
Alive 3,087 (86.5) 1,192 (86.1) 4,279 (86.4)
Death in the first 3 years 394 (11.0) 151 (10.9) 545 (11.0)
Death after 3 years 89 (2.5) 42 (3.0) 131 (2.6)
Location of primary tumor
Gonadal 3,315 (92.9) 1,278 (92.3) 4,593 (92.7)
Retroperitoneal 123 (3.4) 57 (4.1) 180 (3.6)
Mediastinal 132 (3.7) 50 (3.6) 182 (3.7)
Presence of lung metastases
No 2,159 (60.5) 852 (61.5) 3,011 (60.8)
Yes 1,411 (39.5) 533 (38.5) 1,944 (39.2)
Presence of NPVM
No 3,161 (88.5) 1,167 (84.3) 4,328 (87.3)
Yes 409 (11.5) 218 (15.7) 627 (12.7)
Prechemotherapy AFP levels (ng/mL)
Median 49.8 31.0 42.2
Range 0.0-2,007,390.0 0.0-2,420,000.0 0.0-2,420,000.0
Q1-Q3 6.0-585.6 4.4-525.3 5.0-571.1
Prechemotherapy AFP levels (categorized)
, 1,000 ng/mL 2,832 (79.3) 1,085 (78.3) 3,917 (79.1)
1,000-10,000 ng/mL 523 (14.6) 195 (14.1) 718 (14.5)
. 10,000 ng/mL 215 (6.0) 105 (7.6) 320 (6.5)
Prechemotherapy HCG levels (U/L)
Median 43.0 31.0 40.0
Range 0.0-35,000,000.0 0.0-121,23,105.0 0.0-350,00,000.0
Q1-Q3 3.0-1,092.0 2.0-916.0 2.0-1,052.0
Prechemotherapy HCG levels (categorized)
, 5,000 IU/L 2,952 (82.7) 1,125 (81.2) 4,077 (82.3)
(continued on following page)
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TABLE 1. Baseline Characteristics for Patients in the Analysis Set (continued)
Baseline Characteristics
Analysis Set
Total (N 5 4,955)Training (n 5 3,570) Validation (n 5 1,385)
n (%) n (%) n (%)
5,000-50,000 IU/L 315 (8.8) 128 (9.2) 443 (8.9)
. 50,000 IU/L 303 (8.5) 132 (9.5) 435 (8.8)
Prechemotherapy LDH (3ULN)
Median 1.1 1.3 1.2
Range 0.0-121.5 0.1-72.0 0.0-121.5
Q1-Q3 0.8-2.2 0.8-2.9 0.8-2.4
Prechemotherapy LDH (categorized)
# 2.53 ULN 2,802 (78.5) 984 (71.0) 3,786 (76.4)
. 2.53 ULN 768 (21.5) 401 (29.0) 1,169 (23.6)
Type of treatment
Conventional chemotherapy regimen 3,377 (94.6) 1,353 (97.7) 4,730 (95.5)
33 BEP 1,076 (30.1) 582 (42.0) 1,658 (33.5)
33 EP or more 144 (4.0) 23 (1.7) 167 (3.4)
43 BEP or more 1,503 (42.1) 579 (41.8) 2,082 (42.0)
33 VIP or more 20 (0.6) 53 (3.8) 73 (1.5)
33 TBEP or more 194 (5.4) 23 (1.7) 217 (4.4)
33 TIP or more 2 (0.1) 4 (0.3) 6 (0.1)
BEP 1 VIP and/or TIP (minimum three cycles total) 25 (0.7) 2 (0.1) 27 (0.5)
BEP 1 EP (minimum three cycles total) 277 (7.8) 12 (0.9) 289 (5.8)
CBOP/BEP 39 (1.1) 64 (4.6) 103 (2.1)
GETUG13 dose dense 0 (0.0) 10 (0.7) 10 (0.2)
BOP/VIP 97 (2.7) 1 (0.1) 98 (2.0)
High-dose chemotherapy regimena 193 (5.4) 32 (2.3) 225 (4.5)
HD-CE 19 (0.5) 25 (1.8) 44 (0.9)
HD-CEC 3 (0.1) 2 (0.1) 5 (0.1)
HD-CEI 2 (0.1) 0 (0.0) 2 (0.0)
HD-VIP 155 (4.3) 4 (0.3) 159 (3.2)
HD-not further specified 14 (0.4) 1 (0.1) 15 (0.3)
Year of treatment
, 1995 392 (11.0) 61 (4.4) 453 (9.1)
1995-1999 1,020 (28.6) 166 (12.0) 1,186 (23.9)
2000-2004 756 (21.2) 357 (25.8) 1,113 (22.5)
2005-2009 781 (21.9) 474 (34.2) 1,255 (25.3)
2010-2013 621 (17.4) 327 (23.6) 948 (19.1)
Type of study
Trial 1,192 (33.4) 33 (2.4) 1,225 (24.7)
Cohort 2,378 (66.6) 1,352 (97.6) 3,730 (75.3)
Abbreviations: AFP, alpha-fetoprotein; BEP, bleomycin, etoposide, and cisplatin; BOP, bleomycin, vincristine, and cisplatin; CBOP, carboplatin,
bleomycin, vincristine, and cisplatin; CE, carboplatin, and etoposide; CEC, carboplatin, etoposide, and cyclophosphamide; CEI, carboplatin, etoposide, and
ifosfamide; EP, etoposide and cisplatin; HCG, human chorionic gonadotropin; HD, high-dose; IGCCCG, International Germ Cell Cancer Collaborative Group;
LDH, lactate dehydrogenase; NPVM, nonpulmonary visceral metastases; TBEP, paclitaxel, bleomycin, etoposide, and cisplatin; TIP, paclitaxel, ifosfamide,
and cisplatin; ULN, upper limit of normal; VIP, etoposide, ifosfamide, and cisplatin.
aAny patient who received at least one cycle of high-dose chemotherapy was classified among the high-dose chemotherapy regimen categories (eg,
someone receiving 23 BEP 1 13 HD-VIP was classified as HD-VIP).
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prognostic variables. Graphical assessment of linearity
(Data Supplement) showed that the effect of age on pro-
gression was linear, whereas the effect of AFP and hCG was
log-linear (log-2 transformation).
The ULN of LDH proved to have a relationship with PFS akin to a
three-step function with cut points located close to 13 ULN and
2.53ULN (Data Supplement). As such, it was categorized, using
the single threshold of 2.53 ULN, based on clinical relevance.
All candidate interactions were included in the model
(global test P , .0001).
The final IGCCCG Update model is presented in Table 3.
Consistent with the original classification, the presence of
NPVM (hazard ratio [HR] 5 6.61 [95% CI, 4.62 to 9.46])
and amediastinal primary tumor (HR5 2.68 [95% CI, 2.04
to 3.53]) were the most important prognostic factors. The
IGCCCG Update model also highlights two new adverse
prognostic variables. Every decade-of-life increase trans-
lates into a 25% increase in the risk of progression. The
presence of lung metastases translates into a 62% increase
in the risk of progression compared with patients without
lung metastases. The final IGCCCG Update model was
robust across year of treatment, geographical region, and
trial versus nontrial patients (data not shown).
Nomograms for Calculating Prognosis
For improved readability, the graphical representation
of the final IGCCCG Update model is presented in two
separate nomograms: one for patients with NPVM
and the other for patients without NPVM. These are
shown in Figure 3 and made available as a web appli-
cation (https://www.eortc.org/IGCCCG-Update).14
Performance of the IGCCCG Update Prognostic Model
The IBS is a measure of prediction error ranging from 0
(perfect accuracy) to 1 (totally inaccurate). The IBS in the
training set was 0.10.
The time-dependent 3-year AUC was 0.76 (95% CI, 0.73 to
0.78), showing the ability of the prognostic score to ac-
curately rank patients’ risk of progression based on their
baseline prognostic factors (Data Supplement). The final
TABLE 2. Update of IGCCCG Survival Probabilities
Original IGCCCG Prognostic Groups
Original IGCCCG Survival Estimates (1997)
Updated Estimates Based on Patients With
Nonseminoma With Prechemotherapy IGCCCG
Prognostic Groups Available
5-Year PFS (95% CI) 5-Year OS (95% CI) 5-Year PFS (95% CI) 5-Year OS (95% CI)
Good 89 (87 to 91) 92 (90 to 94) 90 (89 to 91) 96 (95 to 96)
Intermediate 75 (71 to 79) 80 (76 to 84) 78 (76 to 80) 89 (88 to 91)
Poor 41 (35 to 47) 48 (42 to 54) 54 (52 to 56) 67 (65 to 69)
Abbreviations: IGCCCG, International Germ Cell Cancer Collaborative Group; OS, overall survival; PFS, progression-free survival.
2,496 1,505 1,350 1,212 1,038 886Poor
2,066 1,696 1,562 1,386 1,211 1,031Intermediate
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2,540 2,062 1,728 1,500 1,282 1,095Poor
2,094 1,936 1,774 1,579 1,393 1,194Intermediate
4,942 4,658 4,235 3,753 3,217 2,813Good





FIG 2. Survival probabilities and 95% CI according to original IGCCCG prognostic groups for (A) PFS and (B) OS. IGCCCG, International Germ Cell
Cancer Collaborative Group; OS, overall survival; PFS, progression-free survival.
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IGCCCG Update model also demonstrated excellent cali-
bration to predict 3-year PFS in the training set (Data
Supplement).
Independent Validation
In the validation set, the IGCCCG Update model had an IBS
of 0.11, a 3-year AUC of 0.74 (95% CI, 0.70 to 0.77), and
equally good calibration (Data Supplement).
DISCUSSION
The international IGCCCG Update Consortium database is
the largest source of information on metastatic GCT
worldwide. In this report, we analyzed the data of 9,728
patients with metastatic NSGCT treated between 1990 and
2013. The majority of patients in the database were treated
according to international guidelines with three cycles of
bleomycin, etoposide, and cisplatin or four cycles of EP in
patients with good prognosis and four cycles of bleomycin,
etoposide, and cisplatin or equivalent conventional-dose
regimens in patients with intermediate and poor
prognosis.15,16 Only a minority of patients received dose-
intensified regimen such as dose-dense or high-dose
chemotherapy.17–20
Compared with the results of the original IGCCCG cohort, in
this modern series, patients with NSGCT from all prognostic
groups experienced substantially improved OS. The dif-
ferences were most striking in patients with poor prognosis
GCT, in whom OS and PFS improved by 19% and 13%,
respectively. By contrast, PFS among patients with good
and intermediate prognosis NSGCT was only slightly better
than that in the original IGCCCG report. This suggests that
improved first-line treatment (chemotherapy and surgery)
might have had the greatest impact on patients with poor
prognosis NSGCT, whereas all prognostic groups benefitted
from more effective salvage strategies.
This large multicenter database capturing modern type
treatments over a period of more than 20 years confirms
previous smaller series that also reported better outcomes
in more recently treated patients with NSGCT.2,5,19,21 These
improvements might have resulted from stage migration
because of earlier diagnosis and better diagnostic tools,
improved supportive care, superiority of cisplatin- and
etoposide-based first-line treatment over other combina-
tions, use of upfront dose-intensified regimens, more
stringent use and higher quality of postchemotherapy
surgery, better salvage strategies in nonresponding or re-
lapsing patients, more stringent guideline adherence,
centralization of care at experienced expert centers, or a
combination of these factors.2–7,16 Additionally, the avail-
ability of the original IGCCCG classification itself helped to
resolve the confusion from heterogenous previous classi-
fications and to guide appropriate treatment duration.22
Given 5-year PFS and OS survival probabilities of 78%
(95% CI, 77 to 79) and 87% (95% CI, 86 to 87) across all
prognostic groups, metastatic NSGCT is, together with
seminoma, the most curable metastatic solid cancer in
males.
An important finding of the present analysis is that the
original IGCCCG classification as published in 1997 still
distinguishes three prognostic groups among patients with
metastatic NSGCT with significantly different PFS and OS
probabilities. However, our model highlights the consid-
erable heterogeneity in prognosis within the original
IGCCCG groups, as shown in the Data Supplement.
Moreover, we identified increasing age and the presence of
lung metastases as additional adverse prognostic factors
that could explain some of these heterogeneities. Addi-
tionally, the strong negative prognostic impact of marker
elevation seen in patients without NPVM becomes much
less relevant when NPVM is present.
TABLE 3. Hazard Ratios of the Final Prognostic Model
Variables Values of Interacting Variables Used for Computation Hazard Ratio 95% CI
Age (10 years increase) 1.25 1.15 to 1.36
Mediastinal primary 2.68 2.04 to 3.53
Presence of lung metastases 1.62 1.36 to 1.92
Presence of NPVM AFP levels # 30 ng/mL 6.61 4.62 to 9.46
HCG levels # 5 U/L
LDH # 2.53 ULN
LDH . 2.53 ULN Absence of NPVM 1.46 1.18 to 1.81
Presence of NPVM 1.01 0.74 to 1.36
Doubling of AFP levels (for values . 30 ng/mL) Absence of NPVM 1.12 1.09 to 1.16
Presence of NPVM 1.02 0.98 to 1.06
Doubling of HCG levels (for values . 5 U/L) Absence of NPVM 1.07 1.05 to 1.09
Presence of NPVM 1.02 0.99 to 1.04
Abbreviations: AFP, alpha-fetoprotein, HCG, human chorionic gonadotropin, LDH, lactate dehydrogenase, NPVM, nonpulmonary visceral metastases;
ULN, upper limit of normal.
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FIG 3. Nomograms of the final prognostic model for patients (A) without NPVM and (B) with NPVM. The
extreme values of AFP andHCGmarkers on the nomogramswere truncated to the rounded 95%percentile of
the training set (13,000 ng/mL for AFP, 175,000 U/L for HCG). Predicted 3-year PFS below 25% are not
shown, as it corresponds to a combination of baseline prognostic factors rarely seen in the training set. AFP,
alpha-fetoprotein, HCG, human chorionic gonadotropin, LDH, lactate dehydrogenase, NPVM, nonpulmonary
visceral metastases; PFS, progression-free survival; ULN, upper limit of normal.
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The original IGCCCG classification used three categories of
LDH elevation. Elevations above 103 ULN were infrequent
in our series. We found 2.53 ULN to be the most clinically
relevant cutoff value having a high specificity.
Our findings confirm reports of smaller studies that also
suggested age and the presence of lung metastases as
adverse prognostic factors.5,23,24 In particular, the new
IGCCCG Update model shows that the negative prognostic
impact of age can, in some cases, be more important than
any other prognostic factor, with the exception of the
presence of NPVM and primary mediastinal GCT. The
reasons for the adverse prognosis with advanced age are
unknown and seem to be not related to an increased
treatment-related mortality. In our series, there was no
evidence that patients’ age influenced the choice of
treatment. Dose reductions or treatment delays may be
responsible for the adverse effect of age, but these
particular data were not collected. Focusing on the
treatment of older patients with germ cell tumor should
therefore become a priority for further prospective
studies.
Inadequate tumor marker decline is another validated
adverse prognostic factor that identified patients with poor
prognosis NSGCT who benefitted from treatment intensi-
fication.19However, postchemotherapy marker decline was
not captured in sufficient numbers in the IGCCCG Update
database to be incorporated in the multivariate IGCCCG
Update model.
As available trial data used the original IGCCCG classifi-
cation for treatment stratification, we suggest that this
classification remains the reference standard for treatment
decisions in daily practice. However, a nomogram adding
the two new variables, presence of lung metastases and
age, as well as a new LDH cutoff of 2.53 ULN instead of
1.53 ULN allows for an improved and more granular in-
dividual prognostic assessment in patients with first-line
metastatic NSGCT. Although this tool appears more
complex than the original IGCCCG classification, it can be
easily accessed via a web-based application (https://
www.eortc.org/IGCCCG-Update).14 In future trials, pa-
tients with a particularly favorable prognosis in the no-
mogram may be subjected to de-escalation strategies to
further reduce treatment burden in patients likely to be
cured. In contrast, trials evaluating dose-escalation strat-
egies should be pursued in patients with the worst prog-
nosis according to the new IGCCCG Update model.
In conclusion, OS of patients with first-line metastatic
NSGCT has improved over the last 20 years. However,
despite these improvements, more than 30% of patients
with poor prognostic features may still die of their disease.
The original IGCCCG classification retains its relevance as a
reference for treatment decisions in daily practice. The new
IGCCCG Update model includes age and lung metastases
as additional adverse prognostic factors and uses a single
cutoff of LDH at 2.53 ULN. A web-based calculator
(https://www.eortc.org/IGCCCG-Update) based on the re-
sults of the IGCCCG Update analysis allows improved and
more granular individual prognostic assessment14 and can
help to shape strategies for future trials.
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